| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8753665 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
| US8846072 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
| US8153661 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
| US8153149 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
Posimir is owned by Durect.
Posimir contains Bupivacaine.
Posimir has a total of 4 drug patents out of which 0 drug patents have expired.
Posimir was authorised for market use on 01 February, 2021.
Posimir is available in solution, extended release;infiltration dosage forms.
Posimir can be used as method for providing sustained local anesthesia for at least 24 hours.
The generics of Posimir are possible to be released after 15 September, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 1, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(17 years from now) | |
Posimir is owned by Innocoll.
Posimir contains Bupivacaine.
Posimir has a total of 1 drug patent out of which 0 drug patents have expired.
Posimir was authorised for market use on 01 February, 2021.
Posimir is available in solution, extended release;infiltration dosage forms.
The generics of Posimir are possible to be released after 12 January, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 1, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: NA
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic